radiation – Page 20 – Oral Cancer News

Head and Neck Cancer Patients Benefit in Multidisciplinary Clinics

Source: Journal of Clinical Oncology Head and neck cancer (HNC) is a multidisciplinary condition. Multi-modality treatment is standard, especially the use of chemoradiation. Proper imaging (CT, MRI and PET), more accurate pathologic assessment and thoroughly tailored treatment plans that limits radiation fields and doses and take into consideration surgical options that minimize morbidity (endoscopic and robotic procedures) are essential. Furthermore, dental, swallowing, speech, nutritional, financial and social support are also cornerstones in this comprehensive approach. However, the most important function might be the role of the nurse navigator in order to offer true coordinated care for our patients. Within William Beaumont Oncology Network we initiated multi-disciplinary clinics for HNC in January 2010 in which our specialists meet the patients together after discussion at the tumor board to streamline management. Methods: In this initial analysis we studied 15 randomly chosen patients’ way through our health care system in 2009, and compared with 15 randomly chosen patients in 2010, after the initiation of the Multi-Disciplinary Clinic. All patients had biopsy verified HNC, the vast majority being squamous cell carcinomas, and were stage III or stage IV. The radiation techniques were unchanged during study and treating physicians remained the same as well. Results: The first group of patients that did not go through our multi-disciplinary clinic had a mean time of 59 days (range 4-156) from pathologic diagnosis to start of radiation. Corresponding mean time for patients going through the multi-disciplinary clinics was 33 days (range 18-86), a decrease of 44%. Conclusions: Coordinated [...]

Oral Cancer Foundation News Team - A2011-06-13T09:22:14-07:00June, 2011|Oral Cancer News|

Boys and HPV Vaccine: The Facts

Source: Forbes Magazine CNN reports on a study that argues that boys should get vaccinated for the human papilloma virus (HPV), which causes cervical cancer in women. But it misses the main reason that boys should be getting jabs of either Merck‘s Gardasil or GlaxoSmithKline’s rival Cervarix. Cue CNN: Men also carry the human papillomavirus, the virus that can lead to male cancers and genital warts. And they could spread HPV to their sexual partners, putting those people at risk for cervical cancer. So the HPV vaccine, that is often recommended for girls, should extend to boys as well, say researchers from Innsbruck Medical University in Austria. Their study was presented at the meeting of the American Urological Association on Tuesday. …. In the study, Dr. Michael Ladurner Rennau and his colleagues tested 133 men, between 7 months to 82 years old for the presence of HPV, one of the most common sexually transmitted infections. They used DNA extraction. They found 18.8% of the examined foreskins had the low-risk HPV genotypes and 9.77% had the high-risk HPV. via Males should get HPV vaccine too, study says – The Chart – CNN.com Blogs. Of course, the reason there’s not a big push to vaccinate men for HPV is because genital warts are treatable and penile and anal cancers are rare. And saying, “Let’s vaccinate your son so that the women he sleeps with won’t get HPV” is an uncomfortable and probably unconvincing approach for pediatricians to take with parents. Girls — [...]

Oral Cancer Foundation News Team - A2011-05-23T12:25:32-07:00May, 2011|Oral Cancer News|

Low-Dose Sorafenib may Boost Treatment for Head and Neck Cancer

Source: Darrell E. Ward Ohio State University Medical Center Adding low doses of the targeted agent sorafenib to the chemotherapy and radiation now often used to treat head and neck cancer might significantly improve patient care and quality of life, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). The findings suggest that adding sorafenib would maintain treatment efficacy while permitting the use of lower doses of chemotherapy and radiation and decreasing the treatment's harsh side effects. The triple combination was well-tolerated in an animal model. About 49,200 new cases of head and neck cancer are expected in the U.S. this year, and 11,500 people are expected to die of the disease. Treatment is often unsuccessful because the tumors become resistant to both chemotherapy and radiation therapy. "This pre-clinical study suggests that using low-dose sorafenib along with chemotherapy and radiation could have significantly milder side effects while maintaining effectiveness," says researcher and principal investigator Dr. Pawan Kumar, assistant professor of otolaryngology and a neck surgeon at the OSUCCC - James. "Our findings provide a scientific rationale to evaluate this combination strategy through a clinical trial," Kumar added. The results of the laboratory and animal study are published online in the journal Molecular Cancer Therapeutics, and they include the following: Sorafenib sensitized tumor cells to chemotherapy and radiation treatment by down-regulating DNA repair proteins (ERCC-1 and XRCC-1), and it decreased tumor angiogenesis [...]

Oral Cancer Foundation News Team - A2011-05-18T13:14:39-07:00May, 2011|Oral Cancer News|

Ultrasound as effective as CT scans for most diagnoses, reducing the dangers of radiation

Source: www.medicalnewstoday.com Author: staff For diagnosing head and neck ailments, tests that use radiation are always less desirable than those that don't. Otolaryngologists have a wide range of techniques available to them, including CT or "CAT" scans, MRI and ultrasound. CT uses significant radiation and MRI a lower amount, but ultrasound is a non-invasive, non-radiating technique. It does not require injection of radioactive contrast material and has no side effects. Now, a new study by Tel Aviv University exploring the efficacy of expensive and invasive CT scans has found that, in some cases, they don't offer a clinical advantage over a simple, inexpensive ultrasound procedure. In his study, Dr. Michael Vaiman of Tel Aviv University's Sackler Faculty of Medicine compared the efficacy of CT versus ultrasound scans for locating vertebral arteries in the throat, an important assessment that must be completed before a surgeon operates in the neck area of the body. After comparing the outcomes of 250 CT scans with 500 ultrasound images, he concluded that there is no advantage to using CT scans for most of these procedures, especially those that are used to locate anomalies in the neck to map major arteries before surgery can take place. Dr. Vaiman's results were published in the March issue of the European Archives of Oto-Rhino-Laryngology. When scans are sound CT scans combine X-rays with highly sophisticated computers to produce a number of pictures of the interior of the body. Traditionally, doctors have relied on these scans to find neck arteries [...]

Oral Cancer Foundation News Team - A2011-05-13T12:21:24-07:00May, 2011|Oral Cancer News|

High Interest in HPV and EGRF When Referring to Head and Neck Cancer

Source: MedScape Today May 12, 2011 (London, United Kingdom) — The hottest topic in head and neck cancers is the role of human papillomavirus (HPV) in the disease, although there is also a lot interest in treatment with EGRF inhibitors, especially the second-generation products, according to an expert here at the European Society for Therapeutic Radiology and Oncology 11th Biennial Conference. HPV has only been associated with head and neck cancer in the last few years, but it is now clear that patients who are positive for the virus have a better prognosis, said Cai Grau, MD, DMSC, professor of oncology at Aarhus University Hospital, Denmark. He chaired a session during which both hot topics were discussed. "These patients have a better prognosis, irrespective of treatment, and their risk of a second cancer is virtually zero," added session participant Lisa Licitra, MD, medical oncologist at the Istituto Nazionale per lo Studio e la Cura dei Tumori in Milan, Italy. However, there is a difference between patients in the United States and those in Europe with regard to risk, she told meeting attendees. For American patterns, Dr. Licitra cited the analysis published last year in the New England Journal of Medicine (2010;363:24-35), which reported a risk model for death from oropharyngeal squamous cell carcinoma on the basis of HPV status, pack-years of tobacco smoking, and tumor and nodal stage. In this 266-patient cohort, 43% were low risk, 30% were intermediate risk, and 27% were high risk. Dr. Licitra reported that when [...]

Oral Cancer Foundation News Team - A2011-05-12T10:12:51-07:00May, 2011|Oral Cancer News|

Spouses of Head/Neck Cancer Patients More Inclined to PTSD

Source: MedScape Today Partners of patients with newly diagnosed head and neck cancer are significantly more likely to meet research criteria for post-traumatic stress disorder (PTSD) than patients themselves, according to a study presented here at the Society of Behavioral Medicine 32nd Annual Meeting and Scientific Sessions. Donna Posluszny, PhD, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, and colleagues from there and from the University of Texas, Arlington, Texas, found that 8 of 20 partners of patients with head and neck cancer (20%) had a mean score on the PTSD Checklist (also known as the PCL) of 50 or higher, compared with only 2 of 40 patients (5%). Patients who score at least 50 on the PCL meet the criteria for PTSD. "This is not a formal diagnosis of PTSD but for research purposes, a score of 50 or higher is meaningful," Dr. Posluszny told delegates. "And we were very surprised to find that partners of patients with newly diagnosed head and neck cancer experience greater amounts of traumatic stress than patients themselves do." For the study, investigators recruited 40 dyads (2 individuals regarded as a pair) where the partner was considered to be a "romantic" partner. Some 78% of the patients were male, while most partners were female; all but a small minority were married. Almost all were white, and, as a cohort, they were somewhat better educated and made more money than the majority of patients with head and neck cancer. Sixty-five percent of them also had [...]

Oral Cancer Foundation News Team - A2011-05-09T09:49:39-07:00May, 2011|Oral Cancer News|

Michael Douglas turns alarming diagnosis into resources for Montreal hospital

Source: TheStar.com The atmosphere was electric when elegant, beleaguered actor Michael Douglas appeared at New York Fashion Week with his beautiful wife, Catherine Zeta-Jones. The glamourous couple had come out to support their designer pal Michael Kors, whose 30th anniversary show was part of the February shows at Lincoln Center. Like many fans, I breathed a sigh of relief when I saw the 66-year-old actor, looking chic in his tailored cashmere. Last summer, Douglas had been diagnosed with Stage 4 throat cancer. We had all said our prayers. This week, in gratitude to the doctor and hospital that helped save his life, Douglas appeared at a gala benefit in Montreal for the McGill Head and Neck Cancer Fund. But he was flying solo: Zeta-Jones, who was recently diagnosed and treated for bipolar II disorder, was at work on a film in the United States. Their family has gone through some unspeakably tough trials, but it appears things are happily back on track. At the gala, the dapper Douglas posed for countless pictures and chatted with guests, adamant about spreading the word that cancer can be beaten and a positive attitude is key. Free of the disease for three months now, Douglas told the crowd that his cancer had gone undiagnosed by doctors in the U.S. While on vacation at his farm outside Mont Tremblant in 2010, Douglas sought a second opinion from Dr. Saul Frenkiel, a head and neck surgeon at Montreal’s Jewish General Hospital. The chilling news: Douglas had [...]

Oral Cancer Foundation News Team - A2011-05-06T09:29:07-07:00May, 2011|Oral Cancer News|

Michael Douglas compliments Canadian health care

Source: The Globe and Mail Hollywood star Michael Douglas offered up high praise for Canadian health care on Tuesday in a nod to the Montreal medical staff who made the breakthrough diagnosis of his throat cancer. Mr. Douglas said a doctor at Montreal’s Jewish General Hospital detected the disease that had eluded specialists in the United States. In gratitude, the Oscar winner agreed to add a new role to his résumé: fundraising draw for Canadian medical research. The actor travelled to Montreal from New York on Tuesday to act as leading man for McGill University’s annual fundraiser for head and neck cancer research. In an interview at a Montreal ballroom where he was about to be honoree for the evening, a dapper-looking Mr. Douglas said getting the news was like being “hit by a truck.” Yet when it came, he said, he had suspected it for months. He said he’d been having bothersome symptoms over the course of nine months: pain in his throat, in the back of his gums and up toward his ears. He consulted various ear, nose and throat doctors and was prescribed antibiotics for what was thought to be an infection. But while summering last year in Quebec’s Mont Tremblant, where he shares a home with his wife, actress Catherine Zeta-Jones, Mr. Douglas went to see Dr. Saul Frenkiel at the Jewish General, a McGill teaching hospital. The doctor put a tongue depressor in the actor’s throat. “I looked in his eyes and I immediately knew [...]

Oral Cancer Foundation News Team - A2011-05-05T09:49:17-07:00May, 2011|Oral Cancer News|

U of A study finds ways to help end dry mouth in cancer patients

Source: e! Science News For patients suffering from cancer in the mouth or throat, a recent study shows that a treatment called submandibular gland transfer will assist in preventing a radiation-induced condition called xerostomia. Also known as dry mouth, xerostomia occurs when salivary glands stop working. University of Alberta researcher Jana Rieger likens the feeling of xerostomia to the experience of the after-effects of having surgery and anesthetic—but the feeling is permanent. While the importance of healthy saliva glands may be an afterthought for some patients when battling cancer, the long-lasting effects create a number of problems for them when they are in remission. "We need saliva to keep our mouths healthy," said Rieger. "Without saliva, people can lose their teeth, dentures don't fit properly and the ability to swallow and speak is severely altered." The study conducted by Rieger, a speech language pathologist in the Faculty of Rehabilitation Medicine, looked at functional outcomes—speech changes, swallowing habits and the quality of life of patients with mouth and throat cancers—as they received two different types of treatments prior to and during radiation. The first group of patients underwent the submandibular gland transfer. This method was pioneered by Hadi Seikaly and Naresh Jha at the University of Alberta in 1999. The transfer involves moving the saliva gland from under the angle of the jaw to under to the chin. Prior to this procedure, the saliva gland was in line for the radiation. Seikaly says, "Most patients, when they are cured from cancer, [...]

Oral Cancer Foundation News Team - A2011-05-05T09:37:29-07:00May, 2011|Oral Cancer News|

HPV & oral sex: link to increase oral cancer in men

Fort Worth— Dana Wilson is one of an estimated 20- million Americans who have HPV which caused cancer in his tongue and neck. Dana remembers getting the news after going to the doctor to have a lump in his neck checked. "It was a moment that you would probably bleep me for saying on air," Dana said. "It was one of those oh, moments." Dr. Jerry Barker is an oncologist at Texas Oncology in Fort Worth and said there is much to be learned about HPV. A recent study suggested that open mouth kissing could be a way to transmit the virus--but Dr. Barker said one thing is certain. "There is clearly a distinct correlation between head and neck cancer and the number of oral sexual partners in a patient's lifetime," Dr. Barker said. "It's an epidemic of human papillomavirus worldwide." Dr. Barker said the virus is increasing at about 2% to 3% a year--approximately the same rate as head and neck cancers--and today fewer Americans smoke. "It's interesting that ten or twenty years ago the majority of men and women who have head and neck cancers had heavy smoking and drinking histories," Dr. Barker said. "Now it tends of be young, non-smokers that are getting these cancers. Dana was treated with a combination of radiation and chemotherapy--today he is cancer free and mentors other head and neck cancer patients. "Was I shocked? Yea," Dana said. "Because probably like a lot of people my initial reaction was HPV, that's a [...]

Oral Cancer Foundation News Team - A2011-05-07T05:18:38-07:00May, 2011|Oral Cancer News|